Atopic dermatitis: lebrikizumab shows efficacy in phase 2b trial

  • Guttman-Yassky E & al.
  • JAMA Dermatol
  • 26 Feb 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Lebrikizumab, an anti-IL-13 monoclonal antibody, is associated with clinical improvements in patients with atopic dermatitis, according to results from a phase 2b trial.

Why this matters

  • Lebrikizumab may represent a potentially useful new treatment option if these results are replicated in phase 3 trials.

Key results

  • Lebrikizumab was associated with greater improvements in the Eczema Area and Severity Index compared with placebo.
    • −41.1% for placebo.
    • −62.3% for lebrikizumab 125 mg every 4 weeks (P=.02 vs placebo).
    • −69.2% for lebrikizumab 250 mg every 4 weeks (P=.002 vs placebo).
    • −72.1% for lebrikizumab 250 mg every 2 weeks (P<.001 vs placebo>
  • Treatment-emergent adverse events were reported in:
    • 46.2% of patients who received placebo,
    • 57.5% of patients who received lebrikizumab 125 mg every 4 weeks,
    • 48.8% of patients who received lebrikizumab 250 mg every 4 weeks, and
    • 61.3% of patients who received lebrikizumab 250 mg every 2 weeks.

Study design

  • 280 patients with atopic dermatitis were randomly allocated to placebo (n=52) or lebrikizumab 125 mg every 4 weeks (n=73), 250 mg every 4 weeks (n=80), or 250 mg every 2 weeks (n=75).
  • Funding: Dermira, Inc.

Limitations

  • Relatively small treatment groups.